AGP Picks
View all

Coast To Coast Tribune
Provided by AGP

Coast To Coast Tribune: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Coast To Coast Tribune.

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

Press releases published on May 30, 2026

UPST DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Upstart Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action – UPST
May 30, 2026

UPST DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Upstart Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class Action – UPST

Indeterminate GlobeNewswire
ThinkCareBelieve: Week 71 of the Trump Administration 2.0
May 30, 2026

ThinkCareBelieve: Week 71 of the Trump Administration 2.0

Indeterminate GlobeNewswire
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
May 30, 2026

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Indeterminate GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages POET Technologies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – POET
May 30, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages POET Technologies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – POET

Indeterminate GlobeNewswire
ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026
May 30, 2026

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

Indeterminate GlobeNewswire
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
May 30, 2026

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Indeterminate GlobeNewswire
SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES
May 30, 2026

SES AI DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages SES AI Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SES

Indeterminate GlobeNewswire
Dusty Cars Announces New Content for Securing a Professional 1960s Mercedes Valuation
May 30, 2026

Dusty Cars Announces New Content for Securing a Professional 1960s Mercedes Valuation

Indeterminate EIN Presswire
Jason McDonald Consulting Agency Announces New Content on Marketing Consulting Services
May 30, 2026

Jason McDonald Consulting Agency Announces New Content on Marketing Consulting Services

Indeterminate EIN Presswire
Ourian Plastic Surgery Announces Updated Content on Breast Reduction with PPO Insurance
May 30, 2026

Ourian Plastic Surgery Announces Updated Content on Breast Reduction with PPO Insurance

Indeterminate EIN Presswire
NUAI DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages New Era Energy & Digital, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – NUAI
May 30, 2026

NUAI DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages New Era Energy & Digital, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – NUAI

Indeterminate GlobeNewswire
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
May 30, 2026

Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About

Indeterminate GlobeNewswire
World Vape Day 2026: One Switch – Everyone Wins
May 30, 2026

World Vape Day 2026: One Switch – Everyone Wins

Indeterminate GlobeNewswire
Día Mundial del Vapeo 2026: Un cambio: todos ganan
May 30, 2026

Día Mundial del Vapeo 2026: Un cambio: todos ganan

Indeterminate GlobeNewswire
Hari Vape Sedunia 2026: Satu Peralihan – Kemenangan untuk Semua
May 30, 2026

Hari Vape Sedunia 2026: Satu Peralihan – Kemenangan untuk Semua

Indeterminate GlobeNewswire
Dia Mundial do Vape 2026: Uma Mudança, Todos Ganham
May 30, 2026

Dia Mundial do Vape 2026: Uma Mudança, Todos Ganham

Indeterminate GlobeNewswire
JELLY TIDE [URGENT REPORT 2026]: The Shocking Rise of JellyTide Gummies—What Consumers Need to Know About the Viral Wellness Trend
May 30, 2026

JELLY TIDE [URGENT REPORT 2026]: The Shocking Rise of JellyTide Gummies—What Consumers Need to Know About the Viral Wellness Trend

Indeterminate GlobeNewswire
Momcozy Launches Plus Baby Wipes Built for Every “Messy Milestone”: 99% Purified Water, 8″ × 8″, Independently Certified by Intertek
May 30, 2026

Momcozy Launches Plus Baby Wipes Built for Every “Messy Milestone”: 99% Purified Water, 8″ × 8″, Independently Certified by Intertek

Indeterminate GlobeNewswire
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
May 30, 2026

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

Indeterminate GlobeNewswire
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 30, 2026

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Coast To Coast Tribune

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.